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IDENTIFYING AND TARGETING ADAPTIVE CHANGES TO BET INHIBITION I N
OVARIAN CANCER

Christopher John LaFargue, M.D.

Advisory Professor: Anil K. Sood, M.D.

Abstract

Purpose: To identify combination strategies using Bromodomain and Extra-Terminal Domain (BET)
inhibitors in a mechanism driven fashion to maximize anti-tumor activity, and to determine the efficacy
of BET inhibitor combinations in pre-clinical ovarian cancer mouse models.

Experimental Design: We used a novel, previously uncharacterized pan-BET inhibitor, CN210,
for all in vitro (MTT, apoptosis, protein expression, reverse phase protein array (RPPA) analysis and
in vivo (orthotopic mouse model)) experiments. The poly (ADP-ribose) polymerase (PARP) inhibitor
olaparib, as well as the mechanistic target of rapamycin (mTOR) inhibitors rapamycin and INK-128
were also used. Statistical analyses of in vitro and in vivo experiments were performed using either
Student t test or Mann-Whitney test with a p value < 0.05 considered significant (sig). RPPA data was
analyzed by Cluster 3.0 using median value and the heat maps were generated by Java Treeview.

Results: Eight ovarian cancer cell lines were screened using MTT assays with CN210 to determine
the most and least sensitive. HeyA8 and OVCAR8 ip1 cells displayed the greatest degree of
sensitivity whereas OVCAR4 and OVCAR5 cells were the most resistant. We next examined the
previously reported synergistic combination of olaparib and BETi and found only modest effects using
in vitro and in vivo applications. RPPA analysis was then performed on all four cell lines after CN210
treatment revealing that activation of the mTOR pathway appeared to be an early adaptive response
to BET inhibition. Decreased cell viability and increased apoptosis were seen with the addition of an
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mTORC1 or dual mTORC1/2 inhibitor to CN210 compared with CN210 alone. Notably, we found that
decreased Akt activation and increased Rictor activation after CN210 treatment served as a possible
marker for the increased response seen with CN210 and INK-128 combination. Lastly, we
demonstrated a significant reduction in tumor weight using CN210/INK-128 combination treatment in
an orthotopic ovarian cancer mouse model.

Conclusions: RPPA analysis identified mTOR activation as an early adaptive change to BET
inhibition in ovarian cancer cells. Combination of BET and dual mTORC1/2 inhibitors led to robust
anti-tumor responses, supporting the inclusion of these drugs into future clinical trials.
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Introduction
Epidemiology and treatment of ovarian cancer
Ovarian cancer is the deadliest gynecologic malignancy in the developed world. It is estimated
that in 2019 there will be 22,530 new cases of women with ovarian cancer, and 13,980 deaths
resulting from this disease in the United States (1). The three main histologic types of ovarian cancer
are epithelial, germ cell, and sex-cord stromal, with the epithelial type accounting for ~90% of all
ovarian cancers. As the overwhelming majority of women afflicted with ovarian cancer will have an
epithelial histology, the focus of the work presented here will be primarily concentrated on this specific
type. Although both the incidence and mortality for epithelial ovarian cancer in the United States has
decreased over the past 15 years (2), it still remains the 5th leading cause of cancer death in women
(1). One significant reason for such a large mortality rate relative to the incidence is that epithelial
ovarian cancer is often diagnosed at an advanced stage (Stage 3 or 4). In fact at the time of diagnosis,
37% of women will already have stage 3 disease, and 28% have stage 4 (2). The reasons for this
unfortunate characteristic of ovarian cancer are primarily two-fold. First, typical symptoms of ovarian
cancer such as abdominal bloating, feeling full quickly, diarrhea/constipation, and vague abdominal
discomfort, overlap with many common and benign gastrointestinal disorders. As such, these
symptoms are often attributed to non-worrisome diseases and may be ignored for a long period of
time without further clinical evaluation. Second, despite numerous well-intentioned efforts (3-5), there
remains no valid screening test for ovarian cancer in the general or “low-risk” population. Accordingly,
although women diagnosed with stage I ovarian cancer have a five year survival rate of 83-89%, the
majority will be diagnosed at an advanced stage with five year survival rates ranging from 18-46% (2,
6). It is now well known that women who harbor a genetic mutation in either the breast cancer
susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2) are at a substantially
increased risk for ovarian cancer, and fall into a separate category than the general population (7).
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For women who do not have a genetic predisposition to ovarian cancer, historical risk factors have
included age >50, early menarche or late menopause, infertility, and nulliparity (8).

Table 1. Five year overall survival in ovarian cancer patients by FIGO Stage at diagnosis (2,
6). This figure contains information obtained from Torre, L. A., B. Trabert, C. E. DeSantis, K. D.
Miller, G. Samimi, C. D. Runowicz, M. M. Gaudet, A. Jemal, and R. L. Siegel. 2018. Ovarian cancer
statistics, 2018. CA Cancer J Clin 68: 284-296; and Heintz, A. P., F. Odicino, P. Maisonneuve, M.
A. Quinn, J. L. Benedet, W. T. Creasman, H. Y. Ngan, S. Pecorelli, and U. Beller. 2006. Carcinoma
of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J
Gynaecol Obstet 95 Suppl 1: S161-192.

FIGO Stage at Diagnosis

5 Year Overall Survival (%)

All stages

47

Ia

89

Ib

86

Ic

83

IIa

70

IIb

65

IIIa

46

IIIb

41

IIIc

32

IV

18
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The primary treatment of epithelial ovarian cancer is surgical cytoreduction with the intent to
remove all visible disease, followed by adjuvant platinum and taxane chemotherapy. Surgical
cytoreduction involves removing the uterus, bilateral fallopian tubes and ovaries, omentum, and any
other organ that can be safely removed which contains tumor (small or large intestine, spleen,
diaphragm, section of liver). The time to recurrence (progression-free survival, or PFS) and time to
death (overall survival, or OS) are the longest in women who have no visible disease remaining at
the conclusion of their initial operation (9). Although there are a variety of factors that affect the
recurrence rate of ovarian cancer, ultimately 70% of women with advanced stage disease will develop
relapsed disease and require further treatment (10).
Until recently, the treatment of recurrent epithelial ovarian cancer was relatively simple, with
only a handful of available chemotherapeutic agents to choose from. The mainstay treatments
consisted of retreatment with a platinum agent (if deemed platinum-sensitive), paclitaxel, topotecan,
liposomal doxorubicin, and gemcitabine (10). As shown in Figure 1, 2014 marked a turning point in
the treatment of both primary and recurrent ovarian cancer. New classes of drugs such as
angiogenesis inhibitors, PARP inhibitors, and immunotherapies have now attained FDA approval,
with different and complex indications for each of them. In light of this emergence of novel therapies,
the number of women currently living with ovarian cancer along some spectrum of its disease course
is a remarkable 225,000, far exceeding the annual incidence of 22,530 mentioned above. While these
novel therapies offer significant promise for many women, they too are limited by the development of
adaptive resistance, in which the cancer cells acquire new ways to render the drugs ineffective (11).
Recurrent ovarian cancer is almost never a curable disease, and the majority of women will spend
the remainder of their life switching from one drug to another once progression occurs. This
unfortunate course of the disease underscores the importance of developing novel therapies that can
prolong the duration of time spent living with cancer without sacrificing quality of life.
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Figure 1. Evolution of ovarian cancer drug approvals (12, 13). This figure was adapted with
permission from Anil K. Sood, MD. It also contains information obtained from Administration, F. D.
2019. Drugs@FDA; and Kelland, L. 2007. The resurgence of platinum-based cancer chemotherapy.
Nat Rev Cancer 7: 573-584.
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Therapy predicting tool and application in ovarian cancer
Since the completion of the human genome project nearly 20 years ago, combined with the
high-throughput advances of genomic sequencing today, the field of targeted cancer therapy has
become the mainstay for the development of new cancer treatments (14). The concept behind
targeted cancer therapy lies in developing anti-cancer drugs that specifically target altered cellular
pathways in each individual cancer, rather than treating all patients with a standard or “one shoe fits
all” chemotherapy. For example, even though two women may both have epithelial ovarian cancer, if
their underlying tumors have different molecular alterations, then each woman would receive a
treatment specifically tailored to their abnormal cellular pathway. While there has been a myriad of
new anti-cancer drugs developed using this methodology, only few have shown meaningful impact
on patient survival and been incorporated into clinical practice (14). Rather than discarding these
“failed” drugs altogether, efforts were undertaken to repurpose them for use in other cancer types or
against alternative aberrant pathways through the development of the therapy predicting tool (TPT).
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Figure 2. Overview of the therapy prediction tool (15). This figure was adapted from Villar-Prados,
A., S. Y. Wu, K. A. Court, S. Ma, C. LaFargue, M. A. Chowdhury, M. I. Engelhardt, C. Ivan, P. T. Ram,
Y. Wang, K. Baggerly, C. Rodriguez-Aguayo, G. Lopez-Berestein, S. Ming-Yang, D. J. Maloney, M.
Yoshioka, J. W. Strovel, J. Roszik, and A. K. Sood. 2019. Predicting Novel Therapies and Targets:
Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther 18: 421-436. It was
printed with permission from Elsevier, the owner of Molecular Cancer Therapeutics, through license
number 4582190290701.
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In brief, the TPT is an algorithm that uses publically available gene and protein expression
datasets (such as The Cancer Genome Atlas and the Genotype-Tissue Expression project) to identify
genes or proteins that are differentially expressed between normal and cancer cells, and that also
confer a difference in patient survival (15, 16) (Figure 2). Previous research has demonstrated the
utility of applying the TPT to repurpose targeted cancer therapies for use in ovarian cancer (15).
Specifically, BRD4 (a member of the bromodomain and extra-terminal domain (BET) proteins) was
found to be overexpressed in ovarian cancer compared to normal ovarian tissues (Figure 3A), and
ovarian cancer patients with high levels of BRD4 had significantly worse overall survival (15) (Figure
3B). These and other findings led to the conclusion that inhibitors of the BET family of proteins (BETis)
may have potential clinical use in the treatment of ovarian cancer.
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Figure 3. Overexpression of Brd4 in ovarian cancer. (A) GTEx analysis comparing expression of
Brd4 in ovarian cancer (red box) to expression in normal ovarian tissue (blue box). (B) Overall survival
curves for patients with ovarian cancer from TCGA datasets comparing high Brd4 expression (red
curve) to low Brd4 expression (green curve) in patient tumors (P <0.02) (15). This figure was adapted
from Villar-Prados, A., S. Y. Wu, K. A. Court, S. Ma, C. LaFargue, M. A. Chowdhury, M. I. Engelhardt,
C. Ivan, P. T. Ram, Y. Wang, K. Baggerly, C. Rodriguez-Aguayo, G. Lopez-Berestein, S. Ming-Yang,
D. J. Maloney, M. Yoshioka, J. W. Strovel, J. Roszik, and A. K. Sood. 2019. Predicting Novel
Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther
18: 421-436. It was printed with permission from Elsevier, the owner of Molecular Cancer
Therapeutics, through license number 4582190290701.
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BET proteins and their role in cancer
The bromodomain and extra-terminal domain family of proteins consist of Brd2, Brd3, Brd4,
and Brdt, and function as epigenetic readers during the process of gene transcription. Specifically,
they bind to acetylated histone residues and other nuclear proteins at gene promoters and enable
mRNA transcription to proceed by releasing the stall of RNA polymerase II at the transcription start
site (17-19). All four proteins share two conserved N-terminal bromodomains (BD1 and BD2) which
serve as the location for binding to acetylated regions (17, 18). Once BET proteins are recruited to
the promoter site through this interaction, they interact with various other proteins and transcription
factors involved in the gene transcription process (p-TEFb, Mediator complex, Jmjd6, TWIST, p53,
c-Jun, AP2), most notably RNA polymerase II, to allow transcription to continue (Figure 4A) (17, 18).
BET proteins are located primarily at promoter and enhancer regions, and even more so at superenhancers, which are regions comprised of multiple enhancers that display a high density of Mediator
complex and master transcription factors (18-20). This is particularly important as the genes regulated
by super-enhancers encompass the fundamental cell identity and also tend to be the genes most
downregulated when BET proteins are inhibited (21-23). BET proteins play a critical role in cellular
growth, as demonstrated by the embryonic lethality that results with homozygous deletion of Brd2 or
Brd4 (24-27).
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Figure 4. Mechanism of BET proteins and their inhibitors. (A) BET proteins bind to acetylated
histones at promoter or enhancer regions and recruit factors such as P-TEFb and MEDIATOR
complex. Interactions between these factors, in addition to interaction with RNA Polymerase II,
releases the stall of RNA Pol II at the transcription start site allowing transcription to proceed. (B) In
the presence of BET inhibitors, BET proteins are no longer able to bind to acetylate histones or other
factors at promoter regions, preventing the transcription of the specific downstream genes. RNA Pol
II, RNA polymerase II. AC, acetylated histone. TSS, transcription start site.

Multiple small molecule inhibitors of BET proteins (BETis) have been synthesized and studied
in the pre-clinical setting for their use as anti-cancer therapy. BETis function by binding to specific
bromodomains within the BET family, preventing the binding to acetylated histones and other critical
transcription factors. As the BET proteins are sequestered by BETis, the transcriptional machinery is
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no longer able to release the stall of RNA polymerase II leading to termination of the specific
downstream transcript (Figure 4B). The primary rationale for targeting BET proteins in cancer cells
derives from three main findings. First, various human cancers demonstrate overexpression of Brd2
and Brd4, as mentioned above (15, 20, 28). Second, genetic expression profiling of various tumors
has revealed BET proteins as essential genes that neoplastic cells require for their continued survival
(28-31). Lastly, NUT midline carcinoma (NMC) is a type of undifferentiated squamous cell carcinoma
defined by a genetic translocation between either the BRD4 or BRD3 gene and the NUT gene on
chromosome 15q14 (32, 33). The resulting Brd4-NUT or Brd3-NUT fusion protein blocks cellular
differentiation and treatment using a small-molecule inhibitor of Brd4, JQ1, demonstrated an antiproliferative effect in patient-derived xenograft models (17). In addition, JQ1 treatment of both
leukemia and multiple myeloma cell lines resulted in a significant decrease in MYC expression, which
is known to play a significant role in the neoplastic processes of both cancers (31, 34, 35). BET
proteins play a crucial role in the survival of various cancer types, and mechanisms to inhibit their
effect have demonstrated promising anti-tumor activity.
The preclinical findings regarding the use of BETis as anti-cancer agents have led to the
initiation of multiple phase I clinical trials. OTX015 has been tested in acute leukemia, non-Hodgkin’s
lymphoma, NMC, castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC),
and glioblastoma (36-40). The highest response rates were found in NMC ranging from 33-50%, while
in the hematologic malignancies response rates ranged from 0-12%, and no responders were
identified in the remaining solid tumor groups (36-40). Despite the fact that there were no responders
in the remaining solid tumor groups, five patients with CRPC and two patients with NSCLC had
prolonged stable disease (37). CPI-0610 was tested in non-Hodgkin’s lymphoma with two complete
and one partial response (41). GSK525762 and TEN-010 are two additional BETis that were tested
in patients with NMC and demonstrated a 20-67% response rate (42, 43). Lastly, BAY1238097 was
examined in eight patients with stage IV solid tumors and showed no responses, however the study
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was terminated early due to dose limiting toxicities (DLTs). Although this last study was terminated
due to DLTs, the other studies above report that BETis are generally well-tolerated with predominant
side-effects including bone marrow suppression (anemia, neutropenia, thrombocytopenia),
gastrointestinal disturbance (diarrhea), fatigue, and bilirubin increase (36-43). While it appears that
the strongest signal from BETi use lies in patients with NMC or hematologic malignancies, it is
important to consider the paucity of data in patients with other solid tumors.

Poly (ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer
The PARP family of proteins (PARP1, PARP2, PARP3) are part of the cellular DNA repair
machinery that function in the repair of single-stranded DNA breaks (SSBs) that occur within cells on
a regular basis (44). When PARP is inhibited or inactive, the cell is unable to repair these SSBs which
causes a stall at the replication fork during DNA replication and the subsequent progression to a
double-stranded DNA break (DSB) (45, 46). The cell is able to repair these DSBs however, using the
high-fidelity homologous recombination DNA repair (HRR) pathway (45, 46). It is known that ~1020% of women will harbor germline mutations in either BRCA1 or BRCA2, which are integral proteins
in the HR repair pathway (47-49). Without the ability to repair DSBs, cells either die or allow potentially
oncogenic genetic aberrations to pass unchecked through the cell cycle. PARP inhibitors (PARPis)
rely on the principle of synthetic lethality in which the deficiency of two or more mechanisms results
in cellular death, whereas the deficiency of only one mechanism does not (44, 50). Women with
germline BRCA1/2 positive ovarian cancer lack one functional copy of either BRCA1 or BRCA2 in
every cell in their body, while their tumor cells lack any functional copies. PARPis exploit this
phenomenon as the SSBs and subsequent DSBs that will occur in normal cells are able to be repaired
by the remaining functional copy of BRCA1 or BRCA2, while the resulting DSBs in tumor cells will
lead to cell death (44, 51).
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Currently, there are three FDA approved PARPis used in the treatment of epithelial ovarian
cancer (52-54). All three (olaparib, rucaparib, and niraparib) are indicated for the maintenance
treatment of recurrent cancer if patients demonstrate a complete or partial response to a platinum
agent, regardless of BRCA1/2 mutation status. In women who have BRCA1/2 mutated ovarian
cancer, rucaparib and olaparib are approved in the recurrent setting after 2 or 3 prior lines of failed
chemotherapy. Most recently, olaparib gained FDA approval for maintenance use in women who
have either germline or somatic mutated BRCA1 or BRCA2 ovarian cancer, if they demonstrate
response to first-line platinum-based chemotherapy. The approval for the maintenance treatment of
recurrent cancer is interesting as it includes not only women who harbor BRCA1/2 mutations, but also
those with BRCA1/2 WT or homologous recombination repair “proficient” tumors. In the clinical trials
which led to this indication for each of the PARPis (55-57), although the greatest benefits were seen
in women who had BRCA1/2 mutated tumors, there was still a clear survival benefit in women who
did not. This has driven the question as to why these women still showed a response as the primary
mechanism is thought to be based on synthetic lethality, as mentioned above. One possible
explanation is derived from an alternative mechanism of PARPis that entails “trapping” PARP proteins
at DNA damage sites which can itself lead to mitotic catastrophe and cell death (58). Yet, despite
such profound clinical responses seen across the various indications, emerging drug resistance
remains a concerning threat to the majority of patients treated (59, 60).

mTOR signaling in cancer
The mechanistic target of rapamycin (mTOR) signaling pathway is one of the integral cellular
networks controlling cell growth and proliferation. mTOR is a serine/threonine protein kinase that
associates with various proteins to form two distinct protein complexes, mTORC1 and mTORC2 (61).
While both complexes contain mTOR and share the same three proteins, only the mTORC1 complex
contains regulatory-associated protein of mammalian target of rapamycin (Raptor) and proline-rich
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Akt substrate 40 kDa (PRAS40); whereas the mTORC2 complex contains rapamycin-insensitive
companion of mTOR (Rictor), protein observed with rictor 1 and 2 (protor1/2), and mammalian stressactivated map kinase-interacting protein 1 (mSin1) (61). Importantly, the individual mTOR complexes
display different degrees of sensitivity to rapamycin, with mTORC1 being exquisitely sensitive and
mTORC2 being resistant, aside from long term treatment. Both mTORC1 and mTORC2 respond to
growth factors, however mTORC1 also responds to stimuli such as energy levels, stress, and oxygen
availability. The primary downstream pathways of mTORC1 involve cell growth, cell cycle
progression, autophagy, and cellular metabolism; whereas the downstream pathways of mTORC2
involve cell survival, cytoskeletal organization, and also cellular metabolism (61).
Both mTOR complexes are closely regulated through the phosphoinositide 3-kinase/protein
kinase B (PI3K/Akt) signaling pathway (Figure 5). Stimulatory signals (such as insulin) that activate
PI3K lead to the phosphorylation of Akt, which then directly phosphorylates the tuberous sclerosis 1
/ tuberin (TSC1/TSC2) complex. TSC1/2 functions as a GTPase-activating protein (GAP) for the Ras
homolog enriched in brain (Rheb), which directly activates mTORC1 when bound to GTP. When
TSC1/2 is phosphorylated it is unable to exchange Rheb-GTP for Rheb-GDP, leaving Rheb-GTP to
activate mTORC1 (62). Akt also independently activates mTORC1 through the phosphorylation of
PRAS40, an mTORC1 inhibitor, leading to its dissociation from Raptor and the remainder of the
mTORC1 complex (63-65). Once activated, mTORC1 can interact with a multitude of proteins to
control various key cellular processes. Perhaps the most important of these is the control of protein
synthesis which it activates through the eukaryotic translation initiation factor 4E (eiF4E)-binding
protein 1 (4E-BP1) and S6 kinase 1 (S6K1) (66). Negative cellular growth signals lead to the inhibition
of mTORC1 and occur through both an indirect method involving TSC1/2 and also a direct method
via phosphorylation of Raptor which results in allosteric inhibition of mTORC1 (67, 68). The stability
of the raptor/mTOR complex is dependent on the nutrient state of the cell; high energy states weaken
the interaction and lead to increased cell growth through phosphorylation of S6K1, whereas low
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nutrient states strengthen the interaction which suppresses the catalytic activity of mTOR (69).
mTORC2 is directly regulated by PI3K via the mSin1 subunit that inhibits mTORC2 in the absence of
insulin. When insulin growth factors activate PI3K, the generation of PIP3 relieves this auto-inhibition
and mTORC2 is able to activate its downstream targets (70). Akt can also directly phosphorylate
mSin1, providing an additional mechanism of mTORC2 activation (71). Interestingly, activated
mTORC2 will then phosphorylate other kinases, including Akt at the serine473 residue, which is a
critical step to achieve maximal activation of Akt and its downstream effectors (cell survival and
proliferation) (72). The mTORC2 specific protein Rictor is also required for proper mTORC2
functioning, as knockdown models demonstrated a significant decrease in the activation of Akt (72,
73). Adding more complexity to the mTOR pathway, mTORC2 is also itself regulated by mTORC1
through a negative feedback loop between mTORC1 and PI3K signaling (74, 75).
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Figure 5. Overview of the mTOR pathway (61). This figure was obtained from Laplante, M., and
D. M. Sabatini. 2012. mTOR signaling in growth control and disease. Cell 149: 274-293. It was printed
with permission from Elsevier, the owner of Cell, through license number 4583231368660.
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Deregulation of the mTOR pathway plays a critical role in the development of malignant cells.
Mutations in the regulatory components of the pathway such as PI3K/Akt activation, or loss of Pten,
p53, or Tsc1/2, all have been reported to promote mTORC1 activation (61, 76). Additionally,
overexpression of the mTORC2 substrate Rictor has been observed in many gliomas, and ectopic
expression of Rictor in glioma cells led to an increased malignant phenotype (77, 78). As such, efforts
have been undertaken to target the mTOR pathway for anti-tumor use. Rapamycin analogues, termed
“rapalogs”, have been developed with the goal of inhibiting mTORC1. As mentioned above,
rapamycin leads to the acute inhibition of mTORC1, however inhibits mTORC2 only after long-term
exposure. Given the various roles that mTORC1 and mTORC2 play in normal cellular functioning,
this becomes an important point when designing rational anti-cancer agents. Rapamycin works
primarily through the formation of a complex with the intracellular 12-kDa FK506-binding protein
(FKB12) that interacts with and inhibits mTOR only when part of the mTORC1 complex (79, 80).
There are currently two FDA approved rapalogs for the treatment of human cancers. Temsirolimus is
approved for the first-line treatment of metastatic renal cell carcinoma (RCC) (81). Everolimus is
approved for second-line treatment of metastatic RCC after sunitinib or sorafenib failure,
neuroendocrine tumors of either pancreatic, lung, or gastrointestinal origin, postmenopausal
hormone-receptor positive HER2-negative breast cancer (in combination with exemestane), and for
renal angiomyolipoma and tuberous sclerosis complex (82). Given the numerous feedback loops
regulating the mTOR pathway described above, efforts have also been made to inhibit both mTORC1
and mTORC2 complexes. These dual inhibitors (termed mTOR kinase inhibitors) function as ATPcompetitive catalytic inhibitors of mTOR and therefore block the total kinase activity of mTOR in both
mTORC1 and mTORC2. Pre-clinical data has shown them to produce a wider and stronger inhibition
of the downstream mTORC pathways (83-89). Among others, sapanisertib (MLN01288 or INK-128)
is an example of such a drug which is currently being tested in a phase-1 clinical trial in patients with
advanced non-hematologic malignancies (NCT02412722).
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mTOR inhibitors in ovarian cancer
Aberrant expression of various components of the mTOR pathway has also been identified in
ovarian cancer. Specifically, genetic mutations of PTEN (90), PIK3CA (91), PIK3R1 (92), Akt1/2 (93,
94), and mTOR (95) have been reported in ovarian cancer patients, with an incidence ranging from
1.9-13.3%. Both mTORC1 and mTORC2 were found to be constitutively active in multiple ovarian
cancer cell lines and knockdown of either Raptor or Rictor (discussed above) led to a significant
inhibition of cell proliferation (96). Blockade of both PI3K and mTOR using the dual inhibitor BEZ235
was superior than rapamycin (mTORC1 blockade only) in decreasing cell proliferation as well as
phosphorylation of S6, 4E-BP1, and Akt (96). Additionally, inhibitors of the PI3K/Akt/mTOR pathway
display a greater anti-tumor effect in ovarian cancer cells with high Akt/mTORC1 activity compared
to those with low activity (97-99).
In light of the promising pre-clinical data surrounding PI3K/Akt/mTOR pathway inhibitors,
multiple phase I and phase II clinical trials have been performed examining use in ovarian cancer
patients. While many of the trials have yet to be reported, GOG170-I, which examined temsirolimus
monotherapy therapy in patients with persistent or recurrent epithelial ovarian cancer, displayed an
overall response rate of 9.3% (98). Notably, patients with increased baseline mTORC1 activity had
higher response rates than those who did not (11.8 vs. 5.9%) (98). More recently, results were
reported for the phase Ib clinical trial examining the use of the dual mTOR inhibitor vistusertib with
weekly paclitaxel in high-grade serous ovarian cancer (HGSOC) and squamous cell non-small-cell
lung cancer (NSCLC) (100). In the HGSOC cohort, response rates were impressive at 52% (RECIST
criteria) and 64% (CA125 criteria) (100). These encouraging results suggest that certain ovarian
cancer patients stand to benefit from inhibition of the PI3K/Akt/mTOR pathway. Future studies are
needed to test these agents in larger trials and to examine their potential in combination use with
other targeted therapies.
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BET inhibitors in ovarian cancer
BET inhibitors have also recently been examined for their potential use in ovarian cancer. As
described above, Brd4 was found to be overexpressed in ovarian cancer relative to normal ovarian
tissue (15), suggesting that targeting Brd4 and other BET proteins may result in anti-tumor activity.
While it appears that the primary oncologic driver for BETi-sensitive NMC and hematologic
malignancies is the overexpression of MYC, ovarian cancer cells displayed a profound
downregulation of FoxM1 pathway genes when exposed to JQ1 (101). Interestingly, previous analysis
of TCGA data revealed that the FoxM1 transcription factor network was activated in 87% of highgrade serous epithelial ovarian cancer cases (102). Furthermore, promoter analysis of FoxM1 using
chromatin immunoprecipitation (ChIP) revealed an accumulation of Brd4, suggesting that disruption
of the promoter region through BET inhibition leads to a decrease in FoxM1 expression (101). Brd4
has also been implicated in the expression of ALDH1A1, which plays a key role in the development
of resistance to platinum agents in the treatment of epithelial ovarian cancer (103). Treatment using
JQ1 was able to prevent the continued growth of cisplatin-resistant epithelial ovarian cancer cells in
both in vitro and in vivo settings (104). Additionally, the PD-L1 encoding gene CD274 was found to
be directly regulated by Brd4, linking BET proteins to immune-mediated tumor evasion (105). Normal
cells express PD-L1 on their cell surface to prevent auto-immune destruction, as the interaction with
the PD-1 receptor on T-cells triggers cell death. Tumor cells will often express PD-L1 to exploit this
phenomenon and evade the host immune system. Tumors from ovarian cancer mouse models
treated with JQ1 showed a decrease in the expression of PD-L1 (105), suggesting a possible role for
BETi combination with immune-checkpoint blockade drugs. A phase I clinical trial (NCT03292172) is
currently underway examining the combination of the BETi RO6870810 and the anti-PD-L1 antibody
atezolizumab in advanced ovarian and triple negative breast cancer. BETis have also demonstrated
a synergistic effect with MEK inhibitors to decrease cell proliferation and survival in ovarian cancer
cells (106).
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Dual targeting of BET and PARP proteins has also generated considerable excitement in the
treatment of epithelial ovarian cancer. Multiple studies have shown that the addition of BETis to
PARPis results in synergistic anti-tumor activity in ovarian cancer cells and mouse models (107-109).
Moreover, it has been previously reported that BETis act synergistically with PARPis in HRR pathway
proficient ovarian cancer cells (109), thus providing a potential avenue for patients who may not
experience the full benefit of PARPis. Specifically, they reported that inhibition of BET proteins
suppresses transcription of BRCA1 and RAD51 (another key protein in the HRR pathway), essentially
transforming the cells to HRR pathway deficient which sensitizes them to PARPis (109). Furthermore,
the authors showed a synergistic decrease in tumor weight and ascites volume using both the Brd4
inhibitor JQ1 and olaparib in a BRCA1/2 WT orthotopic ovarian cancer mouse model. Downregulation
of the cell-cycle checkpoint regulator WEE1 and the DNA-damage response factor TOPBP1 after
JQ1 treatment has also been described as a mechanism for the synergy between BETis and PARPis
in HRR proficient ovarian cancer cells (108). An additional mechanism for the induction of HRR
deficiency in HRR proficient ovarian cancer cells includes the depletion of the DSB resection protein
CtIP (C-terminal binding protein interacting protein) (107). Interestingly, JQ1 treatment has also been
shown to reverse multiple mechanisms of resistance to PARPis in ovarian cancer cells (107). These
preclinical data suggest that clinical trials incorporating the combination of BETis and PARPis would
likely demonstrate a positive signal.
Despite the enormous excitement surrounding the use of BET inhibitors in cancer therapy,
there remain multiple issues that prevent them from obtaining widespread clinical use. First, BET
inhibitors appear to have the highest efficacy in NMC, a malignancy driven by either a Brd4-NUT or
Brd3-NUT fusion protein. It is safe to assume that there will be very few cancers with this same
genetic pathophysiology, possibly hindering the rationale for use in other malignancies. Second,
although BET inhibitors do show activity in other tumor types, the response rates are still low (0-12%).
Third, BET inhibitors have only been tested in a minority of solid tumors, perhaps masking an
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astounding response in so-far unexamined cancer types. Last, and perhaps most important,
resistance to BET inhibitors in ovarian cancer has recently been described, mediated by adaptive
kinome reprogramming (110). In order to circumvent many of these issues, it is absolutely necessary
to determine how cancer cells respond to BET inhibition and to investigate whether these changes
reveal other proteins that can be targeted to maximize anti-tumor activity.

Hypothesis and specific aims
Hypothesis: Adaptive changes to BET inhibition in ovarian cancer will identify rational drug
combinations.
Specific Aim 1: To identify early adaptive changes to BET inhibition in ovarian cancer cells and to
develop combination strategies to maximize anti-tumor activity.
Specific Aim 2: Assess the biological effects of combining BET inhibitors with either PARPis or
mTOR inhibitors in murine orthotopic models of ovarian cancer.

21 | P a g e

Materials and Methods
Reagents and antibodies
For the in vitro experiments, we used the BETi CN210, kindly provided by ConverGene;
olaparib was purchased from LC Laboratories (#O-9201), rapamycin was purchased from Selleck
Chemicals (#S1039), and sapanisertib (INK-128) was purchased from Selleck Chemicals (#S2811).
The inhibitors were re-suspended in dimethyl sulfoxide (DMSO; #D2650; Sigma-Aldrich) to make a
working stock of 100 mM (olaparib) or 10mM (CN210, rapamycin, and INK-128). The control for all
our in vitro experiments was DMSO diluted to 1:1,000. For immunoblots, the following antibodies
were used: c-MYC (#5605; Cell Signaling Technology; 1:1,000), AKT (#4691; Cell Signaling
Technology; 1:1000), p-AKT (Ser473) (#4060, Cell Signaling Technology; 1:1000), Raptor (#2280,
Cell Signaling Technology; 1:1000), p-Raptor (Ser792) (#2083, Cell Signaling Technology; 1:1000),
mTOR (#2983 Cell Signaling Technology; 1:1000), p-mTOR (Ser2481) (#2974, Cell Signaling
Technology; 1:1000), p70 S6 Kinase (#2708, Cell Signaling Technology; 1:1000), p-p70 S6 Kinase
(Thr389) (#9234, Cell Signaling Technology; 1:1000), Rictor (#2114, Cell Signaling Technology;
1:1000), and p-Rictor (Thr1135) (3806, Cell Signaling Technology; 1:1000).

Cell line maintenance
All cell lines were maintained in 5% CO2 at 37 °C. Ovarian cancer cells (HeyA8, OVCAR3,
OVCAR4, OVCAR5, OVCAR8 ip1, ID8, SKOV3ip1, Kuramochi, and COV362) were obtained from
the American Type Culture Collection (ATCC) and the University of Texas MD Anderson Cancer
Center Characterized Core Line Core Facility. OVC432 was gratefully obtained from Dr. Ronny
Drapkin (Dana Farber Cancer Center). Kuramochi, HeyA8, OVCAR3, OVCAR4, OVCAR8,
OVCAR432, and SKOV3ip1 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine
serum (FBS) and 0.2% gentamicin sulfate (#50146970; Fisher). OVCAR5, COV362, and ID8 were
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maintained in D-MEM media supplemented with 10% fetal bovine serum and 0.2% gentamicin sulfate.
All in vitro experiments were conducted at 60-70% cell confluence.
The identity of the cell lines used was validated through short tandem repeat DNA analysis
performed by the Characterized Cell Line Core Facility. Mycoplasma detection was performed using
the ATCC PCR Universal Mycoplasma Detection Kit (#30-1012K).

Cell viability assay
Cells were seeded in a 96-well plate and treated for 72 hours with increasing concentrations
of CN210, olaparib, rapamycin, and INK-128. Combination groups contained the same
concentrations as the individual drugs at each specific concentration level. For the majority of the cell
lines tested, 3,000 cells were deposited into each well. After 72 hours, 50 ul of 1.5 mg/ml solution of
MTT (#M2128; Sigma Aldrich) dissolved in PBS was added to each well, followed by incubation for
2.5 hours at 37°C. The media + MTT solution was then removed, 100 µL of DMSO was added to
dissolve the MTT by-product, and the absorbance at 540 nm was recorded for each well. Each
concentration point was replicated in experimental quadruplicates with the OD average of the four
being used for analysis. Combination indexes were calculated by using the program CompuSyn,
version 1.0, 2004.

In Vitro Apoptosis assay
Cells were plated in a 6-well plate in their respective media to reach 60-70% confluence after
24 hours, typically requiring 50,000 cells per well. After 24 hours, the supernatant was removed from
each well and replaced with 3 ml media containing the desired concentration of each drug.
Combination groups contained the same concentrations as the individual drugs being tested. Each
experimental condition was repeated in experimental duplicates. DMSO was used as a control in a
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1:1000 dilution, and untreated cells were used for FITC and PI control staining. After 48 hours, the
media was collected into individually labelled tubes. Each well was then washed twice with sterile
PBS and the cells were trypsinized until detached from the plastic surface. Two mL of media was
then added to each well to neutralize the trypsin and the cells were then added to their respective
tubes containing the originally collected media. Cells were then centrifuged at 2000 rpm for 3 minutes
and the supernatant was discarded. Cell pellets were then washed with cold, sterile PBS x2. Using
the FITC Annexin V Apoptosis Detection Kit I (catalog number 556547, BD Pharmingen, BD
Biosciences), cells were then incubated with both FITC-labeled Annexin V and PI according to the
manufacturer’s protocol. Cells were then incubated in the dark at room temperature (RT) for 30
minutes with gentle vortex every 10 minutes. Annexin V and PI control cells were only incubated with
either Annexin V or PI, respectively. Cells were then transferred to flow cytometry tubes and analyzed
at the MD Anderson South Campus Flow Cytometry Core. The resulting percent of apoptotic cells in
each group was then used for statistical purposes. All experiments were repeated twice at a minimum,
aside from Figure 10.

Immunoblotting
Cells were treated with either 10 uM CN210 or DMSO (1:1000) dissolved in serum containing
media for 48 hrs. To exclude the potential effect of FBS on protein expression changes, cells were
either plated and treated for 24 hours in SFM or plated in SFM for 6 hours followed by the addition of
10uM CN210 dissolved in SFM for the remaining 18 hours.
Cells were then washed twice with PBS and lysed with radioimmunoprecipitation assay buffer
(RIPA) including protease and phospho-preotease inhibitors. To determine protein concentrations,
we used a Pierce BCA Protein Assay Kit (#23225; Thermo Fisher Scientific). Either 20 or 40 ug of
total cell lysate was then loaded and separated on Mini-PROTEAN TGX Gels (B#456-1084, BIO-
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RAD). Proteins were transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA)
at 90V for 90 minutes, blocked with 5% milk for one hour, and then incubated with primary antibody
at 4°C overnight. Membranes were then washed three times x10 minutes with Tris-buffered saline
including 0.1% Tween-20 (TBS-T), and incubated with horseradish peroxidase-conjugate anti-Rabbit
(#7074, Cell Signaling Technologies, 1:2000), or Mouse (GE Healthcare, NA931V, 1:2000) for two
hours. The membranes were then washed again three times x10 minutes in TBS-T, developed using
Western Lightning Plus ECL (#NEL105001EA; Perkin Elmer), and visualized using x-ray film (#FBX57; Phenix). Membranes were re-probed multiple times with different primary antibodies. In order
to remove the previously bound antibodies, membranes were washed with Restore PLUS Western
Blot Stripping Buffer (#46430; Thermo Fisher Scientific) for 10 min and then rinsed in TBS-T followed
by washing twice x5 minutes. The membranes were blocked again for one hour using 5% milk, and
then incubated with primary antibody overnight 4°C.

Reverse Phase Protein Arrays (RPPA)
HeyA8, OVCAR8 ip1, OVCAR5, and OVCAR4 cells were treated with 1 uM CN210 for 48
hours. After the elapsed treatment time, cells were washed twice with PBS and lysed using RIPA
buffer including protease and phospho-protease inhibitors. Protein concentration was determined as
above and the lysate was diluted to a concentration of 1.5 ug/ul. Next, the lysate was mixed with 4x
sample buffer (40% glycerol, 8% sodium dodecyl sulfate, and 0.25 M Tris, pH 6.8) that did not contain
bromophenol blue, and then finally mixed with β-mercaptoethanol in a 1:10 ratio. The samples were
submitted to the MD Anderson RPPA Core Facility and run using a panel of 304 antibodies. Each
experimental condition was performed and submitted as biological duplicates. Full details of the
specific protocol used by the RPPA Core Facility can be found on their website (111).
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In Vivo models
All mice used in this study were female athymic (NCr-nude) mice purchased from Taconic
Farms (Hudson, NY). Mice were treated and cared for in accordance to the guidelines set forth by
the United State Public Health Service policy on Human Care and Use of Laboratory Animals and the
American Association for Accreditation of Laboratory Animal Care. All mouse experiments were also
supervised and approved by the University of Texas MD Anderson Cancer Center Institutional Animal
Care and Use Committee. Mice were approximately 6-8 weeks old at the time of tumor injection.
Tumor cells were grown to 60-70% confluency in their indicated media. Prior to injecting tumor
cells into mice, the cells were washed twice with PBS, and harvested using trypsin-EDTA. After the
addition of FBS-containing media to neutralize the trypsin, cells were then counted and centrifuged
at 1500 rpm for 5 minutes followed by resuspension at the desired concentration in Hanks’ balanced
salt solution (HBSS; Gibco, Carlsbad, CA) prior to injection. OVCAR5 (1x106cells in 200 uL) or
SKOV3 ip1 (1x106 cells in 200 uL) cells were then injected into the peritoneal cavity of each mouse.
For the CN210 and olaparib experiment, mice were treated daily via oral gavage using 100
mg/kg CN210 and/or 50 mg/kg olaparib. In order to deliver CN210 orally, we dissolved CN210 powder
in a 30% solution of Kolliphor (#42966-1 kg; Sigma-Aldrich) diluted in water and adjusted with 1.05
equivalents of 0.1 N HCl for dosing. Sonication was performed, if necessary, to ensure complete
dissolution of the CN210. For experiments containing olaparib, we first created a 86 mg/ml stock
concentration dissolved in DMSO. 349 uL of the stock solution was then added to 2051 uL of 15%
(2-Hydroxypropyl)-β-cyclodextrin (#H107; Sigma-Aldrich) in PBS, to create a final concentration of
12.5 mg/ml. 100 uL was then given via oral gavage for a total delivery of 50 mg/kg. The control group
for the CN210/olaparib experiment received 200 ul of a 50/50 mixture of both solvents used to
dissolve CN210 and olaparib. For experiments containing INK-128 (1 mg/kg), the compound was
dissolved in order with 30% PEG400 (#202398; Sigma-Aldrich) + 0.5% Tween80 (#P5188; Sigma-
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Aldrich) + 5% propylene glycol (#P355-1; Fisher Scientific) in deionized water for a working
concentration of 0.25 mg/ml.
Toxicity was observed after 14 days of daily treatment in the CN210/INK-128 combination
group, manifesting primarily as weight loss and skin effects (scale development). All groups were
given 4 days without treatment, and after resolution of toxicity, treatment was restarted in all groups
at every other day frequency. Necropsy was performed in the CN210/olaparib experiment on D35 (28
days of treatment) or if mice became moribund. Necropsy was performed in the CN210/INK-128
experiment on D42 (35 days of treatment) or if mice became moribund.

Statistical analysis
Statistical analyses of in vitro and in vivo experiments were performed using GraphPad Prism
7. Standard statistical comparison tests such as Student t test, t test with Welch’s correction, and
Mann-Whitney test were used to analyze the data. Importantly, when triplicate values were compared,
normality and variance were determined and the appropriate statistical test was used. When only
duplicate values were available, a t-test without Welch’s correction was used as normality and
variance could not be ascertained. For these analyses, a P value < 0.05 was considered significant.
Results are presented as the mean ± standard deviation of the mean, aside from where indicated.
For both in vivo experiments, we calculated that 10 mice per group would allow for detection
of a 50% decrease in tumor weight and nodules at a power of 80%, with a confidence of 95%. As
there was poor tumor uptake in the control group of the CN210/olaparib combination in vivo
experiment (~43%, 3/7), all mice in every group without any identifiable tumor were excluded from
the analysis of tumor weight or number of tumor nodules. For the CN210/INK-128 combination in vivo
experiment, there was sufficient tumor uptake in the control group (90%) and all mice in every group
were included in the statistical analysis whether tumor was present or not.
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For statistical analysis of the RPPA data, the median of the expression fold-change from three
individual replicas in each condition was plotted in the heat map as log 2 value. The p values
associated with pathways in IPA analysis were calculated using the right-tailed Fisher Exact Test.
Fold change data that did not meet significance (P < 0.05) was not included. The data was then
analyzed by Cluster 3.0 (112) using median value and the heat maps were generated by Java
Treeview (113). Furthermore, an additional heat map was created using GraphPad Prism 7 for only
the mTOR pathway related proteins. Fold change was calculated by dividing the average expression
of CN210 treated cells by the average expression of the DMSO treated cells. Student t test was
performed to determine if the fold change was statistically significant. Fold changes that had P > 0.05
were not included in the additional heat map.
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Results
Sensitivity of ovarian cancer cell lines to BET inhibition
To determine the sensitivity to BET inhibition in ovarian cancer cell lines, MTT assays were
performed using the novel BET inhibitor, CN210. CN210 is a “non-specific” or “pan” small-molecule
BET inhibitor that reversibly binds to the bromodomains of all four BET proteins, thereby preventing
the normal interaction with acetylated histones or transcription factors. Although JQ1 has been
extensively used in previously published research, it is known to have multiple off-target effects which
limits its integration into the clinical setting. To circumvent this, we collaborated with ConverGene
Science who developed CN210 as a novel BET inhibitor with limited off-target effects, making its
translation into humans more feasible.
Initially, a panel of eight ovarian cancer cell lines were screened using CN210 cell viability
assays. As shown in Figure 6, the IC50s ranged from 3.5 uM to 100.7 uM. To best determine the
adaptive changes to BET inhibition in ovarian cancer cells, we decided to compare the cells displaying
high levels of sensitivity to those displaying resistance. OVCAR5 and OVCAR4 cell lines were
identified as the most resistant to BET inhibition with IC50s of 100.7 uM and 20.8 uM, respectively
(highlighted in red). Similarly, HeyA8 and OVCAR8 ip1 cell lines were identified as the most sensitive
to BET inhibition with IC50s of 4.9 uM and 3.5 uM, respectively (highlighted in blue). Notably, OVCAR8
ip1, HeyA8, and OVCAR5 cells possess KRAS mutations, in contrast to OVCAR4 cells.
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Figure 6. Effect of the BET inhibitor CN210 on ovarian cancer cell lines. (Left) Table displaying
individual and average IC50 values for each cell line. (Right) Representative cell viability curves for
the most sensitive and resistant cell lines. Error bars represent the SD. NC; not calculable. M; molar.
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As mentioned above, BET proteins have been reported at high levels at the promoter and
enhancer regions of cMYC in hematologic malignancies. Furthermore, BET inhibition was previously
shown to cause significant downregulation of cMYC in NMC and hematologic cancer cells. To
determine whether BET inhibition had an effect on cMYC levels in ovarian cancer, we examined cell
lysates for cMYC expression after 48 hours of DMSO or CN210 (10 uM) treatment. HeyA8 and
OVCAR4 cells showed a substantial decrease in cMYC levels after CN210 treatment, whereas a
slight increase was observed in OVCAR8 ip1 cells, and no effect was seen in OVCAR5 cells (Figure
7). Interestingly, the two cell lines determined to be the most sensitive to BET inhibition had opposite
effects on cMYC expression levels when treated with CN210. This may imply that the alteration of
cMYC expression due to BET binding at the cMYC promoter is not relevant for the overall BETi
response in ovarian cancer cells. It is important to note however, that the basal expression of cMYC
in HeyA8 and OVCAR8 ip1 cells was substantially different, perhaps masking the true effect of BET
inhibition on cMYC expression in these cell lines.

Figure 7. Effect of BET inhibition on cMYC expression in ovarian cancer cells.
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Effect of CN210 and olaparib combination on ovarian cancer cells
The combination of BET and PARP inhibitors has been recently shown to have a synergistic
treatment effect in ovarian cancer cells (107-109). To determine whether this effect was reproducible
using our specific BET inhibitor, we next performed combination MTT assays with our CN210resistant and sensitive cell lines using CN210 and olaparib (Figure 8). We found that in our two
CN210-sensitive cell lines (HeyA8 and OVCAR8 ip1), there was a synergistic effect at most but not
all individual concentrations. Synergism, as represented by the distance between the green
combination treatment line and the two individual drug treatment lines, was most pronounced
between CN210 concentrations ranging from 0.5 uM to 10 uM, while concentrations lower or higher
than this had only minimally increased effects. The CN210-resistant OVCAR5 cells also displayed
synergism at the same range of concentrations, while OVCAR4 cells had a predominantly
antagonistic effect.
The plots on the right hand side of figure 6 display the log combination indexes (log-CIs) at
each individual concentration for the cell lines. Each point represents the degree of increased effect
in the combination group compared to individual groups at each individual concentration. The further
the values lie below zero, the stronger the synergistic effect at that specific concentration. Values
located on the line signify an additive effect, whereas values above the line signify an antagonistic
effect. Examining the log-CIs for each cell line reveals that olaparib displayed a synergistic effect with
CN210 in all four cell lines, however the degree to which synergism occurred differed at various
concentrations. Every point aside for the two additive ones were in the synergistic range for HeyA8
although most were only slightly below zero. OVCAR8 ip1 cells also had points in the synergistic
range however antagonist interactions were seen at higher concentrations. For the CN210 resistant
cell lines, OVCAR5 cells displayed substantial synergism between CN210 and olaparib at the majority
of concentrations tested, however similar to OVCAR8 ip1 cells, antagonistic effects were seen at
higher concentrations. OVCAR4 cells had the least amount of synergism between the two drugs as
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only 6 of 9 nine possible data points even fit on the graph, two of them being in the antagonistic range,
and four of them being only slightly synergistic.
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Figure 8. Effect of CN210 and olaparib combination on cell viability in CN210-resistant and
sensitive ovarian cancer cell lines.
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To determine if the synergistic decreases in cell viability were caused by an increase in
apoptosis, we next examined the effect of CN210 and olaparib combination using apoptosis assays
(Figure 9). In both of the CN210-sensitive cell lines there was an increase in apoptosis after CN210
and olaparib individual treatments, however only olaparib treatment in HeyA8 cells resulted in a
statistically significant increase. Combination of the two drugs led to an increase in apoptosis
compared to DMSO control, however significance was only reached in HeyA8 cells. Notably, there
was a statistically significant increase in apoptosis between the combination group and each
individual drug in the HeyA8 cell line, signifying an enhanced effect when both drugs were combined.
The effect of combination treatment was less pronounced in the CN210-resistant cell lines. In
OVCAR5 cells, olaparib treatment produced a significant increase in apoptosis compared to DMSO,
while CN210 or the combination group did not. The latter finding is likely due to the wide standard
deviation of the combination group in the OVCAR5 cell line. In OVCAR4 cells, each individual group
and the combination group resulted in a significant increase in apoptosis compared to DMSO.
Importantly, although there was a significant increase seen between CN210 and DMSO, the absolute
difference between these two groups was small. Furthermore, OVCAR4 cells had a surprisingly
higher amount of apoptosis after CN210 treatment than what would be expected from the MTT data
for this cell line. Lastly, although there was no difference between the olaparib group and the
combination group in OVCAR4 cells, there was a significant difference between the CN210 group
and the CN210/olaparib group, suggesting the effect in the combination group was driven primarily
by olaparib.
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Figure 9. Effect of CN210 and olaparib combination on apoptosis in CN210-resistant and
sensitive ovarian cancer cell lines. Error bars represent the SD. Significance reported for each
group compared to DMSO control, except where indicated. *, P <0.05; **, P <0.01; and ***, P <0.001
as determined by the Student t test. ns, non-significant.
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Considering that only one cell line (HeyA8) displayed a significant increase in apoptosis in the
combination group vs. either individual drugs, we next sought to determine if an enhanced effect
could be achieved through varying the treatment time and concentrations used. We chose to use the
OVCAR5 cell line as both the CN210 and combination group did not show a significant increase in
apoptosis compared to control. It stands to reason that this cell line would be the most likely to benefit
from varied concentrations, especially considering the IC50 of CN210 in OVCAR5 cells was ~100 uM
and the previous conditions were examined at only 1 uM CN210. The amount of apoptosis in
OVCAR5 cells was substantially increased by both increasing the concentration of CN210 and also
harvesting the cells after 24 or 48 hours, as compared to the original 72 hours (Figure 10). Cells
treated for 48 hours expectedly had larger amounts of apoptosis than cells treated for 24 hours. When
OVCAR5 cells were treated at 50% of the IC50, ~25% and 80% of cells had undergone apoptosis at
treatment times of 24 and 48 hours, respectively. Cells treated with CN210 at the IC50 displayed ~75%
and 95% apoptosis at 24 and 48 hours, respectively. Varying the concentration of olaparib from 20
to 50 uM (compared to 10 uM originally) did not substantially change the amount of apoptosis for this
drug. Perhaps most interesting was that neither changing the concentrations, nor changing the
amount of treatment time, was able to produce an enhanced effect between CN210 and olaparib.
Considering that this enhanced effect was seen in HeyA8 cells however, the results from Figure 9
suggest that a combination effect between CN210 and olaparib is cell-specific, and is not dependent
on drug concentration or treatment.
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Figure 10.

Effect of varied concentration and treatment time of CN210 and olaparib

combination on apoptosis in OVCAR5 cells. Error bars represent the SD between experimental
duplicates only.

No intergroup comparisons were calculated as biological replicates were not

performed for this experiment.
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Effect of CN210 and olaparib combination in BRCA mutated ovarian cancer cells
As described above, olaparib and other PARPis exert their anti-tumor activity through the
concept of synthetic lethality, in which they exploit the lack of a functional homologous recombination
pathway found in cells that harbor BRCA mutations. To determine whether the homologous
recombination pathway contributed to the ability of CN210 to synergize with olaparib, we examined
the effect of combined treatment in ovarian cancer cells lines containing BRCA mutations. Kuramochi
is a high-grade serous ovarian cancer cell line which harbors a BRCA2 missense mutation (114).
COV362 is also a high-grade serous ovarian cancer cell line which harbors a BRCA1 splice-site
mutation (114). Figure 11 displays the effect of CN210 and olaparib combination in both Kuramochi
and COV362 cell lines. Interestingly, there was a substantial lack of a synergistic effect in both cell
lines compared to the four BRCA WT cells discussed above. Kuramochi cells demonstrated a
synergism between CN210 and olaparib at higher concentrations (CN210 10 uM and 20 uM), as
represented by the log-CIs, however COV362 cells did not show any meaningful synergistic effects.
Examining the effect of combined treatment on apoptosis in COV362 cells revealed that
olaparib produced a significant increase in apoptosis compared to DMSO, whereas neither CN210
nor the combination group did (Figure 12). Furthermore, there was only ~15% apoptotic cells after 48
hours treatment of olaparib at a concentration of 100 uM. Considering that there was ~20% apoptosis
in OVCAR5 cells after 48 hours of 20 uM olaparib treatment, this suggests that the BRCA1 mutation
may in fact hinder the ability of cells to undergo apoptosis in this particular cell line. In the Kuramochi
cell line, CN210, olaparib, and the combination group all significantly increased the amount of
apoptosis compared to DMSO control, however the combination group did produce an effect greater
than the individual drugs themselves. We found it surprising that in both BRCA mutated cell lines, the
response to olaparib was not as pronounced as expected given their efficacy in human patients.
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Figure 11. Effect of CN210 and olaparib treatment on cell viability in BRCA mutated cell lines.
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Figure 12. Effect of CN210 and olaparib treatment on apoptosis in BRCA mutated cell lines.
Error bars represent the SD. Significance reported for each group compared to DMSO control. *, P
<0.05 as determined by the Student t test. ns, non-significant.
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Effect of BETi and PARPi combination In Vivo
To determine whether PARP inhibition could increase the effect of BET inhibition in vivo, we
treated an orthotopic ovarian cancer mouse model with either control, 100 mg/kg CN210, 50 mg/kg
olaparib, or a combination of CN210/olaparib. We used the human ovarian cancer cell line OVCAR5
and injected 1x106 cells intraperitoneally into nude mice to emulate the normal growth environment
of human ovarian cancer (Figure 13A). After 28 days of treatment, there was no difference in mouse
weight across all groups (Figure 13B). While it appeared that there was a decrease in tumor weight
in the combination group compared to control, this finding was not statistically significant.
Furthermore, there was no apparent difference in tumor weight between control and either CN210 or
olaparib treatment alone (Figure 13C). Similarly, all three treatment groups had less tumor nodules
than control, however this was not statistically significant (Figure 13D). Although previously published
literature has reported a large amount of synergy between PARPis and BETis, both our in vitro and
in vivo data did not support this conclusion.
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Figure 13. Effect of CN210 and olaparib combination treatment in an OVCAR5 ovarian cancer
cell mouse model. (A) Schematic overview of in vivo experiment. (B-D) Mouse weight, tumor weight,
and number of tumor nodules at necropsy across all treatment groups. Error bars represent the SEM.
All comparisons between groups in each panel were non-significant.
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RPPA analysis of CN210-resistant and CN210-sensitive ovarian cancer cell lines
Given that we did not observed the kind of effects that have been reported with the
combination of BETis and PARPis in prior studies (107-109), we next sought to determine the
adaptive changes to BET inhibition in ovarian cancer cells. We used RPPA analysis to measure the
protein expression of genes that were altered after CN210 treatment in both our CN210-sensitive and
resistant cell lines (Figure 14 and Figure 15).
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Figure 14. Differential expression of proteins and phosphorylated proteins in CN210-sensitive
cell lines after CN210 treatment, as detected via RPPA. Heat map of proteins which were
significantly different after CN210 treatment (1 uM) for 48 hours compared to DMSO control.
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Figure 15. Differential expression of proteins and phosphorylated proteins in CN210-resistant
cell lines after CN210 treatment, as detected via RPPA. Heat map of proteins which were
significantly different after CN210 treatment (1 uM) for 48 hours compared to DMSO control.
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Protein and phosphorylated protein changes were then uploaded into Ingenuity Pathway
Analysis (IPA) to perform a network analysis. Interestingly, regulation of eIF4 and P70S6K signaling
were highly upregulated in this analysis, suggesting activation of the mTOR pathway after CN210
treatment (Figure 16).

Figure 16. IPA analysis of RPPA data comparing all four treated cell lines to controls. IPA
readout of RPPA data showing upregulation of eIF4 and p70S6K signaling after CN210 treatment.
Shade of bars signifies up or downregulation of specific pathway (dark orange-strongly upregulated,
dark blue-strongly downregulated). -log(p-value) at top signifies strength of association with greater
number corresponding to stronger association.
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Next we analyzed our RPPA results using IPA in the context of protein expression changes
after CN210 treatment between CN210-sensitive and resistant cells. Although both groups displayed
an upregulation of mTOR pathway components (eIF4 and P70S6K signaling), the effect was more
pronounced in CN210-sensitive cells (Figure 17). This was an interesting finding given that one might
expect CN210-resistant cells to use mTOR pathway upregulation as an escape mechanism to cell
death.

Figure 17. IPA analysis of RPPA data comparing CN210-sensitive cells to CN210-resistant
cells after treatment with CN210. Darker shading signifies stronger association with orange
corresponding to upregulation and blue corresponding to downregulation.

Canonical Pathways
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Considering that components of the mTOR pathway were upregulated in all four cell lines
after CN210 treatment, we next examined the expression of individual proteins within only the mTOR
pathway to determine whether the effect extended throughout. Using the IPA pathway analysis tool
and selecting proteins within the mTOR pathway revealed an upregulation of multiple other key
proteins including mTORC2, S6K1, Rictor, Akt, RPS6, and p70S6K (Figure 18).

Figure 18. IPA pathway generator of specific mTOR related proteins. RPPA data examined was
all CN210 treated cells vs. control. Red proteins signifies an increased expression after CN210
treatment, while green signifies decreased expressed. Lines connecting the individual proteins signify
a direct interaction. Red box highlights the specific upregulated mTOR pathway proteins.
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The IPA software uses RPPA data to generate pathways from actual experimental results in
combination with expected changes in proteins based on those results. To examine the expression
changes of only those proteins involved in the mTOR pathway from our RPPA dataset, an additional
heat map was created (Figure 19). Although not every protein resulted in a statistically significant fold
change after CN210 treatment, analysis of those that did revealed a global activation of many mTOR
pathway components. Specifically, activation of PI3K, mTOR, and S6K was observed in all cell lines
after CN210 treatment. Activation of Rictor was seen in HeyA8 and OVCAR5 cell lines. Interestingly
however, CN210 treatment resulted in decreased activation of Akt in OVCAR8 ip1 and OVCAR5 cell
lines, and decreased total Raptor in HeyA8 and OVCAR8 ip1 cell lines.

Figure 19. mTOR pathway specific protein expression changes after CN210 treatment from
RPPA data. Red and green shading correspond to increased (fold change >1.0) and decreased
expression (fold change <1.0) after CN210 treatment, respectively. Only values that were considered
statistically significant (P < 0.05 as determined by the Student t test) were included, expression
changes that were not significant are denoted by an X. (Top) Heat map using a gradient with gray as
the baseline of 1.0. (Bottom) Binary heat map displaying overall direction of protein expression
change after CN210 treatment.
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Importantly, we show that CN210 treatment resulted in upregulation of the entire
PI3K/Akt/mTOR pathway. It appears that expression of mTORC2 is increased after CN210 treatment
as evidenced by the increase in activated and total Rictor. Furthermore, downstream components of
the mTOR pathway such as S6 and P70S6K were also found to be increased after BET inhibition.
Our RPPA data revealed that activation of the mTOR pathway appears to be an early adaptive
change to BET inhibition and could possibly serve as an additional target to increase the anti-tumor
activity of BET inhibitors.

Combined Effect of BET and Rapamycin in ovarian cancer cells
Based on our findings that BET inhibition of ovarian cancer cells leads to mTOR pathway
activation, we next examined the effect of CN210 and mTOR inhibitors on cell viability. As discussed
above, rapamycin is an mTORC1 specific inhibitor which functions by forming a complex with FKBP12
which can inhibit mTOR when it is a part of mTORC1 but not mTORC2. The combination of CN210
with rapamycin produced only modest evidence that there was synergy between the two compounds
(Figure 20). HeyA8 cells appeared to have the most promising synergistic interaction as evidenced
by all points on the logCI graph being negative (far below 0). Although the remaining cell lines
demonstrated synergistic interactions at certain specific concentrations, there was no strong evidence
that rapamycin synergized with CN210 on a global scale. Furthermore, the inherent sensitivity of the
cell lines to CN210 did not appear to play a role in whether synergy between CN210 and rapamycin
occurred.
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Figure 20. Effect of CN210 and rapamycin combination on cell viability in CN210-resistant and
sensitive ovarian cancer cell lines.
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Extending upon the findings from the cell viability analysis, we next analyzed the effect of
CN210 and rapamycin combination on apoptosis (Figure 21). All cell lines except OVCAR4 cells
showed a significant increase in apoptosis after CN210 treatment vs. DMSO. Importantly, the
concentration of CN210 used here was 10 uM (increased from the 1 uM used in the olaparib
experiments) and the treatment time was 48 hours (decreased from the 72 hours used above). This
is likely the explanation for why the cell lines displayed a more robust response to CN210 inhibition.
Rapamycin treatment alone did not result in a significant increase in apoptosis compared to DMSO
in any of the cell lines. All of the cell lines except for OVCAR4 displayed a significant increase in
apoptosis after combined treatment compared to DMSO. Only OVCAR8 ip1 had any evidence of a
potentially enhanced effect with combination treatment, and even this absolute increase amount was
minimal. These findings suggest that inhibiting mTORC1 only, either alone or in combination with
CN210, is not an effective method to increase cell death.
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Figure 21. Effect of CN210 and rapamycin combination on apoptosis in CN210-resistant and
sensitive cell lines. Error bars represent the SD. Significance reported for each group compared to
DMSO control, except where indicated. *, P <0.05; **, P <0.001; and ***, P <0.0001 as determined
by the Student t test. ns, non-significant.
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Combined Effect of BET and INK-128 in ovarian cancer cells
Next, we examined the effect of combining CN210 with a dual mTORC1/2 inhibitor. As
mentioned above, INK-128 is a dual mTORC1/2 inhibitor which functions as an ATP-competitive
inhibitor of mTOR, blocking the phosphorylation of all downstream targets of mTORC1 and mTORC2.
Combination of CN210 with INK-128 produced synergistic decreases in cell viability in both CN210sensitive (HeyA8, OVCAR8 ip1), as well as CN210-resistant (OVCAR5) cell lines (Figure 22). In these
three cell lines, the combination curves (green) lie below the individual drug curves (blue/purple) at
every concentration point, suggesting a global synergistic or at least enhanced effect in decreasing
cell viability. This is also represented in the logCI graphs showing that the majority of the points for
these three cell lines are far below zero. The logCI values for OVCAR4 cells suggest an antagonistic
interaction between CN210 and INK-128 at 50% of the concentrations tested, as can also be seen in
the cell viability curve.
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Figure 22. Effect of CN210 and INK-128 combination on cell viability in CN210-resistant and
sensitive ovarian cancer cell lines.
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The combination of CN210 and INK-128 also led to more impressive results on apoptosis than
combination with rapamycin (Figure 23). CN210 treatment alone resulted in a significant increase in
apoptosis compared to DMSO in every cell line tested. Additionally, HeyA8 and OVCAR4 cell lines
both showed a significant increase in apoptosis with INK-128 treatment alone compared to DMSO.
The combination of CN210 and INK-128 produced a significant increase in apoptosis compared to
DMSO in all four cell lines, similar to what was seen when combined with rapamycin (aside from
OVCAR4). Although no meaningful interactions between CN210 and rapamycin were identified
above, we show here that the CN210/INK-128 combination led to a significantly greater amount of
apoptosis in OVCAR8 ip1 and OVCAR5 cells than either of the individual drugs alone. In fact, the
results from the OVCAR8 ip1 cells suggest a true synergistic interaction between CN210 and INK128 in this cell line.
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Figure 23. Combined effect of CN210 and INK-128 on apoptosis in CN210-resistant and
sensitive cell lines. Error bars represent the SD. Significance reported for each group compared to
DMSO control, except where indicated. *, P <0.05; **, P <0.001; and ***, P <0.0001 as determined
by the Student t test. ns, non-significant.

58 | P a g e

Combined effect BET and mTOR inhibition in a CN210-equivocal cell line
As the combined effect of CN210 with either rapamycin or INK-128 did not appear to be
specific to either CN210-resistant or sensitive cells, we next determined the effect in the CN210equivocal SKOV3 ip1 ovarian cancer cell line. As discussed above, the IC50 for CN210 in SKOV3 ip1
cells was 13.5 uM, falling in the middle between the CN210-sensitive and resistant cell lines originally
selected. Combination treatment of CN210 and rapamycin resulted in a synergistic decrease in cell
viability at the majority of concentrations tested per the log-CI graph. This same effect was also seen
between CN210 and INK-128, however to a lesser extent (Figure 24).
Analysis of the combined effect on apoptosis demonstrated SKOV3 ip1 cells to be particularly
sensitive to CN210 and mTOR inhibition. CN210 treatment alone resulted in a significant increase in
apoptosis compared to DMSO. Both rapamycin and INK-128 treatment alone, as well as in
combination with CN210 produced a significant increase in apoptosis when compared to DMSO.
Interestingly, both CN210/rapamycin and CN210/INK-128 combinations resulted in significant
increases in apoptosis compared to either CN210, rapamycin, or INK-128 alone (Figure 25). This
finding demonstrated that the inherent sensitivity of an ovarian cancer cell line to CN210 does not
predict its sensitivity to combined inhibition of both BET and mTOR proteins.
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Figure 24. Combined effect of CN210 and either rapamycin or INK-128 on cell viability in a
CN210-equivocal ovarian cancer cell line.
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Figure 25. Combined effect of CN210 and either rapamycin or INK-128 on apoptosis in a
CN210-equivocal ovarian cancer cell line. Error bars represent the SD. Significance reported for
each group compared to DMSO control, except where indicated. *, P <0.05; **, P <0.001; and ***, P
<0.0001 as determined by the Student t test. ns, non-significant.

Validation of RPPA mTOR pathway changes after BET inhibition
To determine whether the RPPA results described above were reproducible, we next
performed a series of Western blots to examine the protein expression changes after treatment with
CN210. Notably, the RPPA data was generated from cell lysate after cells were treated with 1 uM
CN210 treatment for 48 hours. As the RPPA platform allows for the detection of relatively small
changes in protein expression, we chose to perform the validation experiments after treating cells
with 10 uM of CN210 for 48 hours, in the hopes of amplifying the previously observed effects (Figure
26).
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CN210 treatment resulted in activation of Rictor (measured from change in phosphorylatedRictor) in all four cell lines, most notably in OVCAR8 ip1, OVCAR5, and OVCAR4 cells. Our heat
maps in Figures 14 and 15 revealed phosphorylated-Rictor to be strongly upregulated in OVCAR8
ip1 and OVCAR5 cell lines, weakly upregulated in HeyA8 cells, and no significant fold change
detected in OVCAR4 cells. CN210 treatment resulted in activation of Raptor in HeyA8 and OVCAR8
ip1 cell lines, with no change observed in OVCAR5 or OVCAR4 cells. Notably, the RPPA analysis
did not include phosphorylated-Raptor. Our heat maps in Figures 14 and 15 did not register any
significant changes of total Raptor in either HeyA8, OVCAR8ip1, or OVCAR5 cell lines, but did show
upregulation in OVCAR4 cells. Furthermore, the additional heat map of only mTOR pathway proteins
in Figure 19 showed a very miniscule decrease of total Raptor in HeyA8 and OVCAR8 ip1 cells, and
a moderate increase in OVCAR4. None of the four cell lines showed any activation of mTOR at the
10 uM CN210 concentration using Western blot, however the RPPA data demonstrated significantly
increased phosphorylated-mTOR in HeyA8, OVCAR8 ip1, OVCAR5, and OVCAR4 cell lines at the
1uM concentration. Using Western blot to examine the effect on a downstream target of mTORC1,
we found increased activation of P70S6K in HeyA8, OVCAR8 ip1, and OVCAR5 cell lines with no
change observed in OVCAR4 cells using 10 uM CN210. Our RPPA data demonstrated strong
activation of P70S6K in HeyA8, OVCAR8ip1, and OVCAR4 cell lines with only slight activation in
OVCAR5. Analysis of the effect on Akt activation at the 10 uM concentration of CN210 did not reveal
any significant change, however the heat map in Figure 19 demonstrated a decrease in Akt activation.
In general, RPPA data tends to identify only subtle changes in protein expression that can be used
to generate hypotheses. Taking this into consideration, our validation experiments were able to aptly
reproduce these trends in protein change after CN210 treatment.
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Figure 26. mTOR pathway protein expression changes after CN210 treatment. Cells were
treated with either 10 uM CN210 or DMSO in 10% FBS for 48 hours and harvested for cell lysate.

To determine if the fetal bovine serum (FBS) present in our cell culture media interfered with
our assessment of protein expression changes, we next treated a select group of cells with 10 uM
CN210 in serum free media (SFM) for 24 hours. In addition, untreated cells were grown in SFM for
the same duration to serve as control. We selected OVCAR8 ip1, OVCAR5, and SKOV3 cells, to
represent our CN210-sensitive, resistant, and equivocal cell lines, respectively. Interestingly, we
found that Akt activation decreased in all three cell lines after CN210 treatment, a result that was
consistent with our RPPA analysis and mTOR pathway specific heat map (Figure 27).

Figure 27. Akt protein expression change after CN210 treatment. Cells were treated with either
10 uM CN210 or untreated in SFM10 for 24 hours and harvested for cell lysate.
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Effect of BET and dual mTOR inhibition In Vivo
To determine the effect of BET and mTOR inhibition in vivo, we selected the SKOV3 ip1 cell
line as it demonstrated enhanced responses between BET and mTOR inhibitors. Furthermore, we
chose to use the dual mTOR inhibitor INK-128 as it achieves a more robust blockade of the mTOR
pathway than the mTORC1-specific rapamycin and other similar rapalogs. We injected 1x106 SKOV3
ip1 cells intraperitoneally into nude mice to emulate the normal growth environment of human ovarian
cancer. Treatment began on day 8 and consisted of 100 mg/kg CN210, 1 mg/kg INK-128, a
combination of both CN210 and INK-128, or control, each given daily via oral gavage. After 35 days
of treatment, necropsy revealed that mice treated with either INK-128 alone or the combination
CN210/INK-128, had a significantly decreased tumor weight compared to control (Figure 28A). Mice
treated with CN210 also had a decreased tumor weight, although this was not statistically significant.
Importantly however, we observed an enhanced effect at decreasing tumor weight when INK-128
was combined with CN210, as the CN210/INK-128 group had significantly decreased tumor weights
compared to the CN210 group alone. Each treatment group (CN210, INK-128, or CN210/INK-128)
also had a decrease in the total number of tumor nodules at necropsy compared to control, however
these findings were not statistically significant (Figure 28B). It is important to mention that mice in the
combination group displayed toxicity to CN210/INK-128 combination treatment at day 14. This was
manifested primarily through decreased body weight and skin changes. All mice were given 4 days
without intervention and then treatment was restarted for all groups on an every other day schedule.
At final necropsy, there was no significant difference in mouse weight between the control and
combination groups (Figure 28C). Mice in the control group developed bulky peritoneal tumors as
well as diffuse nodular disease along the mesentery and intestines. Mice in the individual treatment
groups still had some bulky peritoneal disease but far less diffuse nodular disease (Figure 28D).
Although toxicity emerged in the combination group, once adjusted for and corrected, there was a
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significant benefit to the mice receiving both CN210 and INK-128, compared to both control as well
CN210 treatment alone.

Figure 28. Effect of CN210 and INK-128 combination treatment in SKOV3 ip1 ovarian cancer
mouse model. (A-C) Mouse weight, tumor weight, and number of tumor nodules at necropsy across
all treatment groups. (D) Representative mice images of tumor burden in each treatment group.
Significance reported for each group compared to control, except where indicated. *, P <0.05 as
determined by the Student t test or Mann-Whitney test, depending on normality assumption. ns, nonsignificant.
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DISCUSSION
Key Findings
The key findings of the work presented above is that mTOR pathway activation is an early
adaptive response to BET inhibition in ovarian cancer cells, and that targeting of both BET and mTOR
proteins together can produce enhanced interactions. Specifically, we found that the use of a novel,
clinical-trial ready BET inhibitor combined with a dual mTOR inhibitor produced synergistic decreases
in cell viability, and significant increases in apoptosis. Furthermore, using an orthotopic mouse model,
we showed that CN210/INK-128 combination therapy led to a significant decrease in tumor weight
when compared to control or CN210 treatment alone.

Role of cMYC expression in CN210-treated ovarian cancer cells
Using the therapy prediction tool, we previously identified Brd4 to be upregulated in ovarian
cancer compared to normal ovarian tissue and that there were multiple compounds being used in the
phase 1 clinical setting to inhibit BET proteins. Although BET inhibitors had yet to be tested
specifically in ovarian cancer patients, the data for cancer types it had been tested in demonstrated
only modest response rates. In light of this, we decided to explore the use of combining additional
anti-tumor agents with BET inhibition in the hopes of achieving an improved response that would
ultimately translate into improved patient outcomes.
Previous reports have suggested that cancer cells which overexpress cMYC are the most
sensitive to BET inhibition, predominantly due to an increased localization of BET proteins at the
cMYC promoter and enhancer regions. After screening a panel of ovarian cancer cell lines with
CN210, we selected two lines displaying CN210-sensitivity and two lines displaying CN210resistance, as measured by IC50. Interestingly, CN210 treatment led to substantially decreased cMYC
expression in both HeyA8 and OVCAR4 cells, although HeyA8 cells demonstrated sensitivity to
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CN210 and OVCAR4 cells demonstrated resistance. This finding suggests the presence of alternative
mechanisms of cMYC regulation in ovarian cancer cells other than BET-related promoter interactions.
Additionally, this shows that BET inhibitor-mediated cMYC expression change does not necessarily
correlate with the effect on cell viability in ovarian cancer cells.

Examination of combined BET and PARP inhibition using in vitro and in vivo models
We next sought to examine the combined effect of BET and PARP inhibition in ovarian cancer
models, as previous literature has reported a strong synergistic effect between the two compounds.
While we did detect a synergistic effect at certain concentrations in some cell lines, our overall results
were not consistent with the robust synergy between BET and PARP inhibition previously reported.
One possible explanation for this could be that the majority of previous studies used JQ1 as the BET
inhibitor. JQ1 produces a strong inhibition of BET proteins with an IC50 of ~100 nM, which is a 1001000x fold difference in the IC50s we identified with CN210. Furthermore, JQ1 has been shown to
have multiple off-target effects, which limits its applicability in the clinical realm. Interestingly however,
we did find that the addition of olaparib to CN210 increased apoptosis compared to CN210 alone in
both HeyA8 and OVCAR4 cells, which were the two cell lines showing a downregulation of cMYC
after CN210 treatment. This suggests that cells with decreased levels of cMYC might be more
sensitive to BET/PARP inhibition than those with higher levels. We also examined the effect of altering
the drug concentrations and treatment times in a CN210-resistant cell line to determine whether an
enhanced effect could be produced. At every condition tested, the amount of apoptosis in the
CN210/olaparib combination group essentially mirrored the amount in the CN210 only group, with no
evidence of synergism observed. This suggests that the effect of the combination group was driven
only by the CN210 with no additional contribution from olaparib. Notably, OVCAR5 is a BRCA wildtype (WT) cell line, which may explain the poor contribution from olaparib, however the OVCAR4 cell
line is also BRCA WT and olaparib treatment produced 3x more apoptosis in OVCAR4 cells than in
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OVCAR5 cells. Lastly, using an ovarian cancer orthotopic mouse model, we did not find any
significant difference in tumor weight or number of tumor nodules between the control group and any
of the treatment groups. As will be discussed in the limitations section, the choice of a CN210resistant cell line, in addition to experimental technical difficulties, likely played a role in this result.
Considering that the two CN210-sensitive and resistant cell lines were BRCA WT, we explored
the effect of BET and PARP inhibition in two BRCA mutated cell lines. Overall the results were far
from expected given the efficacy of PARP inhibitors in ovarian cancer patients with BRCA mutations.
Combined treatment with CN210/olaparib in these cell lines did not decrease cell viability to the extent
that it did in any of the four BRCA WT cell lines. In fact, olaparib treatment did not even result in a
significant increase in apoptosis in the BRCA1 mutated cell line (COV362) compared to control. One
possible explanation is that these cell lines have only one mutated copy of BRCA whereas tumor cells
from patients have two mutated copies. Additionally, as neither of the BRCA mutated cell lines
displayed synergy between CN210 and olaparib, this suggests a lack of involvement of BET proteins
in the homologous recombination repair pathway.

Using RPPA analysis to identify adaptive changes to BET inhibition
Given that our findings using BET and PARP inhibitors were not as prominent as previously
reported, we employed RPPA analysis to determine the adaptive changes to BET inhibition. RPPA is
a valuable tool that can be used to identify subtle changes in protein expression after drug treatment
at a high-throughput level. Importing our RPPA results into IPA revealed that multiple components of
the mTOR pathway were upregulated after BETi treatment, suggesting that this pathway could be
targeted to produce a synergistic effect with CN210. Furthermore, there did not appear to be a
difference in this upregulation based on the cell lines’ inherent sensitivity or resistance to CN210.
Analysis of our raw data alone confirmed many of the findings from the IPA, including an interesting
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finding of decreased activation of Akt in OVCAR8ip1 and OVCAR5 cells after CN210 treatment. One
possible explanation for this is due to the multiple feedback loops present within the mTOR pathway,
notably the negative feedback loop between mTORC1 and insulin/PI3K signaling (115).

In vitro assessment of the combined use of BET and mTOR inhibitors
The addition of mTOR inhibition (specifically INK-128) to BET inhibition in ovarian cancer cells
produced a more substantial effect than the BETi/PARPi combination. We found that the addition of
the mTORC1 inhibitor rapamycin to CN210 produced the greatest decrease in cell viability within
HeyA8 and OVCAR5 cells, which again displayed different inherent sensitivity to BET inhibition. As a
treatment alone, rapamycin was not effective in increasing the amount of apoptosis compared to
DMSO. When combined with CN210 in the OVCAR8 ip1 cell line however, it did demonstrate a
significant increase in the amount of apoptosis compared to CN210 or rapamycin alone, although the
absolute amount was small. In addition, the overall effect of the combination group was weak with
only ~20% of cells undergoing apoptosis. This is not surprising given the complexity of the mTOR
pathway containing two main complexes that each have numerous interactions and feedback loops
between various other components. Specifically, mTORC1 inhibition can actually increase Akt
phosphorylation via a decrease in the negative feedback loop with the insulin/PI3K pathway.
mTORC2 however, is still able to activate Akt and other downstream targets involved in cell survival
when only mTORC1 is inhibited.
Combining CN210 with an inhibitor of both mTORC1 and mTORC2, rather than only
mTORC1, produced significant in vitro and in vivo effects compared to CN210 by itself. We showed
that CN210/INK-128 combination treatment produced a synergistic decrease in cell viability in HeyA8,
OVCAR8 ip1, and OVCAR5 cell lines, with a negligible effect on OVCAR4 cells. Analysis of our
apoptosis data revealed that INK-128 by itself was effective in significantly increasing apoptosis
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compared to control in both OVCAR4 and HeyA8 cells, however the absolute differences were small.
Importantly, we found that CN210/INK-128 combination treatment produced a significant increase in
apoptosis in both OVCAR8 ip1 and OVCAR5 cells, with a likely synergistic increase in the OVCAR8
ip1 cell line. As both OVCAR8 ip1 and OVCAR5 cells were shown to have large decreases in Akt
activation after CN210 treatment, this may explain why these two cell lines show an enhanced
interaction between CN210 and INK-128. A major target of the dual mTOR inhibitors is Akt
phosphorylation, so combining them with a compound that produces additional downregulation of Akt
would likely lead to an enhanced effect. Similarly, CN210 treatment also resulted in decreased Akt
expression in the SKOV3 ip1 cell line, as evidenced from Western blot data (SKOV3 ip1 cells were
not included in RPPA analysis). Consistently, we also found a significant increase in apoptosis using
the CN210/INK-128 combination in this cell line.
Perhaps an additional explanation for the observed anti-tumor effect of CN210 in SKOV3 ip1
cells lies in the fact that they possess an ARID1A gene mutation, resulting in a non-functioning protein
(116). ARID1A is a member of the SWI/SNF chromatin remodeling complex which has been shown
to function as a tumor suppressor through its role in the regulation of histone modification (117). Cells
that contain ARID1A gene mutations have altered epigenetic regulation and may rely on epigenetic
readers such as the BET family of proteins to drive oncogenesis. It therefore seems plausible that
BET inhibition might be expected to produce a stronger anti-tumor effect in SKOV3 ip1 cells harboring
an ARID1A mutation, compared to cell lines with functional ARID1A.
To understand why the synergistic response was so pronounced in the OVCAR8 ip1 cell line
we examined the protein expression of mTOR pathway proteins using Western blot after 48hr
treatment with 10 uM CN210. We found that DMSO-treated OVCAR8 ip1 cells had no expression of
p-Rictor whereas the CN210 treated cells had a substantial expression of p-Rictor. As Rictor is only
part of the mTORC2 complex, it corresponds that combining CN210 with rapamycin would not yield
a synergistic effect, whereas combination with a dual mTORC1/2 inhibitor would. We believe that the
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considerable increase in apoptosis after CN210/INK-128 treatment is due to the blockade of Akt
signaling mediated by both CN210 and INK-128, as well as the decreased activation of Rictor using
a dual mTORC1/2 inhibitor. Similarly, OVCAR8 ip1 cells also had an increase of Raptor activation
after 10 uM CN210 treatment, which adds additional strength to the necessity of dual mTORC1/2
blockade. Although as single agents, mTORC1 and dual mTORC1/2 inhibitors did not display
substantial effects in vitro, the addition of a dual mTORC1/2 inhibitor to a BET inhibitor produced
significant effects deserving of further exploration.

Addition of mTORC1/2 inhibition to BET inhibition using an in vivo model
Lastly, we demonstrated using an orthotopic ovarian cancer mouse model that combined
treatment of CN210 and INK-128 produced a significant decrease in tumor weight compared to
control or CN210 only. In addition, mice treated with INK-128 alone also resulted in a significant
decrease in tumor weight compared to control. Our in vivo results were consistent with our in vitro
findings as the SKOV3 ip1 cell line demonstrated a significant interaction between both
CN210/rapamycin and CN210/INK-128 compared to the individual drugs. Although toxicity emerged
in the combination group, this was easily managed by altering the dosing schedule. Importantly,
toxicity emerged early and the final results of the in vivo experiment reflected 21 days on the new
treatment schedule. These findings suggest that if toxicity was carefully monitored, this drug
combination can be moved into a phase 1 clinical trial to determine its anti-tumor effect in human
patients.

Limitations
As eluded to above, there were multiple limitations to this study. One limitation lies in the
usage of RPPA analysis as a tool to detect changes in protein expression after drug treatment. While
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this platform is highly effective in determining subtle changes in protein expression, the results may
not be reproducible, nor correspond to any meaningful effect on cell function. For example, there may
be a 1.05 fold change in a specific protein after drug treatment, but this small degree of change may
not have any actual effect on cellular cell function. It is important to keep these points in mind when
using RPPA analysis as the results are more for hypothesis generation rather than hypothesis
confirmation.
A second limitation of the study involved the orthotopic in vivo experiment using the
combination of CN210 and olaparib. As the cell line chosen for the experiment (OVCAR5) did not
demonstrate a uniformly synergistic interaction between the two compounds, it is no surprise that a
significant interaction was not seen using an animal model. In hindsight, choosing a cell line that
demonstrated a robust combined response between the two compounds would have been a more
apt choice for the experiment. Furthermore, there were multiple technical issues with this experiment.
Mice were treated daily via oral gavage with either control, CN210, olaparib, or CN210/olaparib.
Multiple mice died across all four groups due difficulties administering the drug using the oral gavage
technique. It was surprisingly easy to mistake the trachea for the esophagus and thus multiple mice
died via accidental asphyxiation. Although these technical issues were extensively addressed and
corrected prior to the conclusion of the experiment, a significant number of mice died which decreased
the sample number in each group, certainly limiting the statistical significance.
A third limitation is the choice of BET inhibitor. As briefly mentioned above, CN210 was used
for all experiments because it has been shown to have minimal off-target effects and is thus prepped
for use in the clinical setting. Had JQ1 been used for the experiments, the results might have been
more profound, particularly in combination with olaparib, however this would defeat the purpose of
identifying additional drugs to combine with a compound that cannot be moved into human use.
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Study Implications
Although ovarian cancer remains the deadliest gynecologic malignancy, the development of
multiple new treatment options over the past decade has allowed women to live longer with the
disease than ever before.
While the majority of clinical trials using mTOR inhibitors have been in the endometrial cancer
arena, which are known to have frequent mutations in the PI3K/Akt/mTOR pathway, there have been
multiple trials examining the use of mTORC1 inhibitors in ovarian cancer (NCT01196429, NCT
01065662, NCT01281514, NCT01256268). A phase 1 trial examining the addition of everolimus to
carboplatin and pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer
revealed a response rate of 67% with tolerable toxicities consisting of mainly hematologic and
gastrointestinal (118). Additionally, the mTORC1 inhibitor ridaforolimus was examined in combination
with carboplatin and paclitaxel in a phase 1 trial of solid tumor cancers. Of the 6 women with ovarian
cancer included in the study, 3 had partial responses according to RECIST criteria, 2 had stable
disease, and 1 had progressive disease (119).
Dual mTOR inhibitors have also been examined in women with ovarian cancer. A phase I/II
clinical trial examining the use of the dual mTOR inhibitor AZD2014 (vistusertib) in combination with
paclitaxel in patients with HGSOC or squamous cell NSLC revealed a response rate of 64% in ovarian
cancer patients, with well tolerated side effects (100). The combination of AZD2014 and olaparib has
also been examined in patients with recurrent endometrial, ovarian, and breast cancers. The authors
found that women with ovarian cancer had a 20% response rate with well tolerated toxicities (120).
The clinical testing of BET inhibitors is still in its infancy however, with only a few trials
including women with ovarian cancer. As mentioned above, the majority of clinical trials examining
BET inhibitors are in patients with hematologic malignancies and NMCs. There is currently an ongoing
phase I/IIa clinical trial assessing the effect of the BET inhibitor BMS-986158 plus nivolumab in
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patients with select advanced cancers. Importantly, the dual mTOR inhibitor used in this study (INK128) has also recently been tested in patients with advanced solid tumors (121). Interestingly, patients
receiving this oral drug daily had a 12% response rate, while those receiving it weekly had a 0%
response rate. When combined with weekly paclitaxel, the response rate improved to 18%.
The clinical trials discussed above support the notion that both BET inhibitors and mTOR
inhibitors are tolerable and have activity in the treatment of ovarian cancer. The implications from this
current study suggest that the combination of BET inhibitors and dual mTOR inhibitors would likely
produce enhanced anti-tumor activity in at least some patients. As many of these trials mature and
progress into phase II and phase III studies, it will be interesting to see how durable the responses
are. Additionally, we found moderate synergy between BET inhibition and PARP inhibition in vitro,
yet our results differed from the previously published studies. This suggests a need for future
biomarker development in order to determine which patients may achieve the best response to
PARPi/BETi combination therapy. Our results also implicate Akt activation as possible biomarker for
response to combination BET/mTOR inhibition. Although additional study is needed, we also propose
that mTOR activation may be a mechanism of resistance in patients treated with BET inhibitors.

Future Directions
Future directions of the data presented here entail the development of a phase I clinical trial
to test the safety profile and efficacy of combination CN210/INK-128 treatment. Toxicity will have to
be closely monitored as discussed above in considering our in vivo experiment observations. It will
also be important to carefully examine why some patients respond to combined treatment whereas
others do not, in order to detect new biomarkers. Based on both the in vitro and in vivo work presented
here, we found that the cancer cells which displayed either increased activation of Rictor or decreased
activation of Akt in response to BETi treatment, were the most likely to gain benefit from the addition
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of a dual mTOR inhibitor.

In fact, OVCAR8 ip1 cells demonstrated both an increase in

phosphorylated-Rictor and a decrease in phosphorylated-Akt, and remarkably they were the only cell
line tested to demonstrate a true synergistic effect between BET and dual mTORC inhibition. To
assess the role of these possible biomarkers, a clinical trial could be designed examining combination
therapy in women with recurrent epithelial ovarian cancer. After obtaining a pre-treatment biopsy to
measure Akt and Rictor expression, they would begin treatment with CN210 only. The patients would
then be divided into three groups based on when a 2nd biopsy would be performed. One group would
have an on-treatment biopsy at 1 month, another group at 2 months, and the last group at 3 months.
Akt and Rictor expression would be assessed again on these 2nd biopsies and the change in
expression of the biomarkers would be calculated. INK-128 would then be given to all patients across
groups that demonstrated either an increase or decrease in Rictor or Akt activation, respectively.
This design would not only assess the clinical activity of combination treatment vs. CN210 only within
each group, but would also help determine the ideal time to perform the 2nd biopsy. The time point
of the group that demonstrated the largest difference in outcomes between combination and CN210
therapy would then serve as the standard time to re-biopsy. This could then be further examined in a
larger trial comparing CN210 (+/- INK-128 based on 2nd biopsy) against standard of care treatment
for recurrent epithelial cancer (“dealer’s choice” -- gemcitabine, PARPi, bevacizumab, pegylated
doxorubicin)
In addition, as there are already multiple clinical trials testing BET inhibitors in humans, it is
conceivable to design a trial wherein patients who have progressed through or recurred after BET
inhibitor treatment are given dual mTOR targeting drugs to see if this mitigates or reverses the
resistant phenotype.
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Conclusions
Our preclinical data used RPPA analysis to identify mTOR activation as an early adaptive
change to BET inhibition in ovarian cancer cells. mTOR activation after CN210 treatment was not
specific to either CN210-resistant or sensitive cells. Cells that displayed either a decrease in Akt
activation or an increase in Rictor activation after CN210 treatment had the largest combined effect
of CN210/INK-128 dual treatment. We also determined that synergy between BETis and PARPis
exists, but not to as large a degree as previously reported, suggesting the need for identification of
additional markers to determine response. Lastly, we demonstrated that the combination of CN210
and INK-128 produces a significant decrease in tumor weight using an orthotopic mouse model,
providing a strong rationale for incorporation into future clinical trial design.
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